{
  "experiment_id": "0aace192b506e5d8a02c63e86b41dd2c",
  "task_name": "narrowing_of_broad_synonyms",
  "task_hash": "9dc5c284f909400a12e111d9ec8ba4e5",
  "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
  "system_instructions": "You are a metadata curation assistant. Your task is to help improve and correct metadata \naccording to the specific instructions provided for each task. Be precise, accurate, and \nfollow the guidelines carefully.\n",
  "temperature": 0.0,
  "thinking": true,
  "tools": [],
  "timestamp": "2025-12-11T04:01:36.860167",
  "task_result": {
    "task_name": "narrowing_of_broad_synonyms",
    "num_samples": 10,
    "results": [
      {
        "sample_index": 0,
        "input": {
          "diagnosis": "Neurofibromatosis",
          "assay": "DNA sequencing",
          "tumorType": "Neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of changes:**\n\n1. **diagnosis**: Narrowed \"Neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (the most common and specific form of neurofibromatosis)\n\n2. **assay**: Narrowed \"DNA sequencing\" \u2192 \"whole genome sequencing\" (a specific type of DNA sequencing method from the controlled terminology)\n\n3. **tumorType**: Kept \"Neurofibroma\" as-is since it's already an exact match in the controlled terminology. While more specific subtypes exist (Cutaneous, Plexiform, etc.), there is insufficient context in the input to determine which specific subtype is appropriate.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3058,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1300
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_013gYmxad4qPss1rCxSjLbRX",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific controlled terminology from the Target Schema:\n\n1. **diagnosis**: \"Neurofibromatosis\"\n   - This is broad and could refer to different types of neurofibromatosis\n   - Looking at the enum options, I see:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n   - The most common form is Neurofibromatosis type 1 (NF1), which is what \"Neurofibromatosis\" typically refers to unless otherwise specified\n   - I should narrow this to \"Neurofibromatosis type 1\"\n\n2. **assay**: \"DNA sequencing\"\n   - This is very broad - DNA sequencing encompasses many methods\n   - Looking at the enum options, there are several sequencing methods:\n     - \"whole genome sequencing\"\n     - \"whole exome sequencing\"\n     - \"targeted sequencing\"\n     - \"next generation targeted sequencing\"\n     - \"Sanger sequencing\"\n     - \"bisulfite sequencing\"\n     - \"ERR bisulfite sequencing\"\n     - \"oxBS-seq\"\n     - \"ChIP-seq\"\n     - \"ATAC-seq\"\n     - etc.\n   - The most common general DNA sequencing approaches are:\n     - whole genome sequencing (most comprehensive)\n     - whole exome sequencing (protein-coding regions)\n     - targeted sequencing (specific regions)\n   - Without more context, \"whole genome sequencing\" would be the most comprehensive narrowing of \"DNA sequencing\"\n   - However, \"whole exome sequencing\" is also very common in clinical/research settings\n   - I think \"whole genome sequencing\" is the most appropriate narrowing as it's the broadest form of DNA sequencing\n\n3. **tumorType**: \"Neurofibroma\"\n   - This is already in the enum list, but there are more specific types:\n     - \"Cutaneous Neurofibroma\"\n     - \"Subcutaneous Neurofibroma\"\n     - \"Plexiform Neurofibroma\"\n     - \"Localized Neurofibroma\"\n     - \"Diffuse Infiltrating Neurofibroma\"\n     - \"Massive Soft Tissue Neurofibroma\"\n     - \"Nodular Neurofibroma\"\n     - \"Cellular Neurofibroma\"\n     - \"Atypical Neurofibroma\"\n     - \"Neurofibroma with Degenerative Atypia\"\n   - Since \"Neurofibroma\" is already present in the enum and no additional context specifies a subtype, I'll keep it as \"Neurofibroma\" rather than selecting a more specific variant without justification. I need to reconsider my approach here. The instructions require using exact controlled terminology from the Target Schema. For diagnosis, I'll narrow \"Neurofibromatosis\" to \"Neurofibromatosis type 1\" since that's the most common form. For assay, \"DNA sequencing\" becomes \"whole genome sequencing\" as a specific type. For tumorType, \"Neurofibroma\" appears in the enum, but since the task emphasizes narrowing broad terms and more specific subtypes exist, I should consider whether additional context would justify selecting a more precise variant.\n\nWithout additional clinical details though, I'll maintain \"Neurofibroma\" as it's already a valid enum value and I lack sufficient information to justify selecting a more specific subtype.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of changes:**\n\n1. **diagnosis**: Narrowed \"Neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (the most common and specific form of neurofibromatosis)\n\n2. **assay**: Narrowed \"DNA sequencing\" \u2192 \"whole genome sequencing\" (a specific type of DNA sequencing method from the controlled terminology)\n\n3. **tumorType**: Kept \"Neurofibroma\" as-is since it's already an exact match in the controlled terminology. While more specific subtypes exist (Cutaneous, Plexiform, etc.), there is insufficient context in the input to determine which specific subtype is appropriate."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3058,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1300
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Plexiform Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3058,
          "output_tokens": 1300,
          "total_tokens": 4358
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 1,
        "input": {
          "diagnosis": "NF",
          "assay": "exome sequencing",
          "tumorType": "sarcoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation to the specific, complete diagnostic term for NF1\n2. **assay**: \"exome sequencing\" \u2192 \"whole exome sequencing\" - Narrowed to the precise, complete terminology for this sequencing method\n3. **tumorType**: \"sarcoma\" \u2192 \"Sarcoma\" - Corrected to match the exact controlled terminology capitalization from the schema",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3052,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 898
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01EqqVMLRkzePsM1Aq7v48Xv",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data, I need to narrow broad synonyms to more specific, controlled terminology:\n\n1. **diagnosis**: \"NF\" - This is very broad. Looking at the enum values, \"NF\" could refer to:\n   - \"Neurofibromatosis type 1\" (NF1)\n   - \"NF2-related schwannomatosis\" \n   - There's no general \"NF\" or \"Neurofibromatosis\" in the enum\n   \n   Since NF most commonly refers to Neurofibromatosis type 1 (NF1) when used alone, I should use \"Neurofibromatosis type 1\"\n\n2. **assay**: \"exome sequencing\" - Looking at the enum, I don't see \"exome sequencing\" exactly, but I see:\n   - \"whole exome sequencing\" - This is the more specific, formal term for exome sequencing\n   \n   So I should use \"whole exome sequencing\"\n\n3. **tumorType**: \"sarcoma\" - Looking at the enum, I see:\n   - \"Sarcoma\" - This exists as an exact value in the enum\n   - But there's also \"Malignant Peripheral Nerve Sheath Tumor\" which is a specific type of sarcoma\n   - \"Fibrosarcoma\" - another specific type\n   \n   However, since \"Sarcoma\" itself is in the enum with capital S, and the input has lowercase \"sarcoma\", I should use the exact case from the enum: \"Sarcoma\"\n\nWait, let me re-read the instructions. The task is to \"narrow broad synonyms\" - to replace broad terms with more specific equivalents. \n\nSo:\n- \"NF\" is broad \u2192 should be narrowed to \"Neurofibromatosis type 1\" (the most common interpretation)\n- \"exome sequencing\" is broad \u2192 should be narrowed to \"whole exome sequencing\" (the complete, specific term)\n\n\n- \"sarcoma\" requires careful consideration. While \"Sarcoma\" is in the enum, there are more specific subtypes available. However, without additional context, I'll maintain \"Sarcoma\" as the controlled term.\n\nI'm weighing the specificity of the controlled vocabulary against the need for precise classification. The schema provides \"Sarcoma\" as a valid term, so I'll use it while acknowledging potential for more granular classification if additional information becomes available.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation to the specific, complete diagnostic term for NF1\n2. **assay**: \"exome sequencing\" \u2192 \"whole exome sequencing\" - Narrowed to the precise, complete terminology for this sequencing method\n3. **tumorType**: \"sarcoma\" \u2192 \"Sarcoma\" - Corrected to match the exact controlled terminology capitalization from the schema"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3052,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 898
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3052,
          "output_tokens": 898,
          "total_tokens": 3950
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 2,
        "input": {
          "diagnosis": "Neurofibromatoses",
          "assay": "assay by high throughput sequencer",
          "tumorType": "Nerve Sheath Neoplasm"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"Neurofibromatoses\" (broad plural term for the group of conditions) \u2192 \"Neurofibromatosis type 1\" (specific form, the most common type)\n\n2. **assay**: \"assay by high throughput sequencer\" (broad, general sequencing term) \u2192 \"whole genome sequencing\" (specific high-throughput sequencing method)\n\n3. **tumorType**: \"Nerve Sheath Neoplasm\" (broad category of nerve sheath tumors) \u2192 \"Neurofibroma\" (specific type of nerve sheath tumor commonly associated with neurofibromatosis)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3067,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 939
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01Uj4c9f3xfm7gFzFmCi5f65",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific values from the Target Schema.\n\n1. **diagnosis**: \"Neurofibromatoses\" - This is a broad term referring to a group of conditions. Looking at the enum values, I need to narrow this to a specific type. The options include:\n   - \"Neurofibromatosis type 1\"\n   - \"NF2-related schwannomatosis\"\n   - \"22q-related schwannomatosis\"\n   - \"LZTR1-related schwannomatosis\"\n   - \"SMARCB1-related schwannomatosis\"\n   - \"Schwannomatosis\"\n   - etc.\n   \n   Since \"Neurofibromatoses\" is plural and general, and \"Neurofibromatosis type 1\" is the most common and specific form in the list, I should narrow it to \"Neurofibromatosis type 1\".\n\n2. **assay**: \"assay by high throughput sequencer\" - This is a broad term for sequencing. Looking at the enum values, there are several sequencing options:\n   - \"whole genome sequencing\"\n   - \"whole exome sequencing\"\n   - \"RNA-seq\"\n   - \"targeted sequencing\"\n   - \"next generation targeted sequencing\"\n   - etc.\n   \n   The term \"high throughput sequencer\" is very general. Since we don't have more context, \"whole genome sequencing\" would be a reasonable narrowing as it's a common high-throughput sequencing approach. However, \"RNA-seq\" is also very common. Looking at the options, \"whole genome sequencing\" or \"RNA-seq\" are both viable. Given the lack of specificity in the original term, \"whole genome sequencing\" is a reasonable choice as it's a comprehensive sequencing approach.\n\n3. **tumorType**: \"Nerve Sheath Neoplasm\" - This is a broad category. \n\nConsidering the context of neurofibromatosis, I'll focus on the specific nerve sheath tumor types. The enum values reveal several options like \"Schwannoma\" and \"Neurofibroma\". Given the diagnosis of Neurofibromatosis type 1, \"Neurofibroma\" emerges as the most appropriate choice, as these tumors are characteristically associated with this genetic condition.\n\nThe diagnostic approach using whole genome sequencing provides a comprehensive method to understand the underlying genetic variations. By narrowing the broad terms to these specific identifiers, we can more precisely characterize the tumor and genetic context.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"Neurofibromatoses\" (broad plural term for the group of conditions) \u2192 \"Neurofibromatosis type 1\" (specific form, the most common type)\n\n2. **assay**: \"assay by high throughput sequencer\" (broad, general sequencing term) \u2192 \"whole genome sequencing\" (specific high-throughput sequencing method)\n\n3. **tumorType**: \"Nerve Sheath Neoplasm\" (broad category of nerve sheath tumors) \u2192 \"Neurofibroma\" (specific type of nerve sheath tumor commonly associated with neurofibromatosis)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3067,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 939
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole genome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3067,
          "output_tokens": 939,
          "total_tokens": 4006
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 3,
        "input": {
          "diagnosis": "neurocutaneous syndrome",
          "assay": "spectroscopy",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"magnetic resonance spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Changes made:**\n\n1. **diagnosis**: Narrowed \"neurocutaneous syndrome\" \u2192 \"Neurofibromatosis type 1\" (the most common neurocutaneous syndrome in this research domain)\n\n2. **assay**: Narrowed \"spectroscopy\" \u2192 \"magnetic resonance spectroscopy\" (a specific spectroscopy technique commonly used in clinical/medical research and diagnosis)\n\n3. **tumorType**: Standardized capitalization \"unknown\" \u2192 \"Unknown\" (to match the exact enum value)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3052,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 859
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_0162hYDSQPq6wXo9F4oaBEPG",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific ones from the controlled terminology:\n\n1. **diagnosis**: \"neurocutaneous syndrome\"\n   - This is a broad term. Looking at the enum values, I need to find a more specific neurocutaneous syndrome.\n   - The options include:\n     - \"22q-related schwannomatosis\"\n     - \"LZTR1-related schwannomatosis\"\n     - \"NF2-related schwannomatosis\"\n     - \"Neurofibromatosis type 1\"\n     - \"Noonan Syndrome\"\n     - \"SMARCB1-related schwannomatosis\"\n     - \"Schwannomatosis\"\n     - \"Schwannomatosis-NEC\"\n     - \"Schwannomatosis-NOS\"\n     - \"Sporadic Schwannoma\"\n     - \"Unknown\"\n     - \"Vestibular Schwannoma\"\n   \n   The most common and well-known neurocutaneous syndrome in this list is \"Neurofibromatosis type 1\" (NF1). However, since \"neurocutaneous syndrome\" is very broad and could refer to any of these conditions, and without more specific context, I should probably use \"Unknown\" to be accurate. But wait - the task says to narrow broad terms to more specific ones. If I can't determine which specific one it should be, \"Unknown\" would be appropriate. However, looking at the context of the schema which seems focused on NF-related conditions, \"Neurofibromatosis type 1\" is the most common neurocutaneous syndrome in this domain. I'll go with \"Neurofibromatosis type 1\" as it's the most prevalent.\n\n2. **assay**: \"spectroscopy\"\n   - This is a broad term. Looking at the enum, I need to find specific spectroscopy types:\n     - \"FTIR spectroscopy\" (Fourier-Transform Infrared Spectroscopy)\n",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"magnetic resonance spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Changes made:**\n\n1. **diagnosis**: Narrowed \"neurocutaneous syndrome\" \u2192 \"Neurofibromatosis type 1\" (the most common neurocutaneous syndrome in this research domain)\n\n2. **assay**: Narrowed \"spectroscopy\" \u2192 \"magnetic resonance spectroscopy\" (a specific spectroscopy technique commonly used in clinical/medical research and diagnosis)\n\n3. **tumorType**: Standardized capitalization \"unknown\" \u2192 \"Unknown\" (to match the exact enum value)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3052,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 859
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 3052,
          "output_tokens": 859,
          "total_tokens": 3911
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 4,
        "input": {
          "diagnosis": "Not Applicable",
          "assay": "immunoassay",
          "tumorType": "neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n- **tumorType**: Changed \"neurofibroma\" to \"Neurofibroma\" to match the exact controlled terminology value in the Target Schema (proper capitalization required).\n- **diagnosis** and **assay**: These values already matched the exact controlled terminology and required no changes.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3054,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1179
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01R7yuTLbuLmj5cmYqawx5gg",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data and the Target Schema, I need to check if each value needs to be narrowed or corrected to match the exact controlled terminology.\n\nInput data:\n- diagnosis: \"Not Applicable\"\n- assay: \"immunoassay\"\n- tumorType: \"neurofibroma\"\n\nLet me check each field:\n\n1. **diagnosis**: \"Not Applicable\"\n   - In the schema enum, I see \"Not Applicable\" (with capital N and A)\n   - The input has \"Not Applicable\" which matches exactly\n   - This is fine as is\n\n2. **assay**: \"immunoassay\"\n   - In the schema enum, I see \"immunoassay\" (all lowercase)\n   - The input has \"immunoassay\" which matches exactly\n   - This is fine as is\n\n3. **tumorType**: \"neurofibroma\"\n   - In the schema enum, I see several neurofibroma-related values:\n     - \"Atypical Neurofibroma\"\n     - \"Cellular Neurofibroma\"\n     - \"Cutaneous Neurofibroma\"\n     - \"Diffuse Infiltrating Neurofibroma\"\n     - \"Localized Neurofibroma\"\n     - \"Massive Soft Tissue Neurofibroma\"\n     - \"Neurofibroma\" (with capital N)\n     - \"Neurofibroma with Degenerative Atypia\"\n     - \"Nodular Neurofibroma\"\n     - \"Plexiform Neurofibroma\"\n     - \"Subcutaneous Neurofibroma\"\n   - The input has \"neurofibroma\" (lowercase)\n   - The exact match in the schema is \"Neurofibroma\" (with capital N)\n   - This needs to be corrected to match the exact capitalization\n\nWait, let me re-read the instructions more carefully. The task is to \"narrow broad synonyms\" and replace \"broad, general terms that should be narrowed to more specific, precise terms.\"\n \nI'm uncertain about narrowing the neurofibroma term. While multiple specific subtypes exist, I lack context to definitively select a more precise classification. The general \"Neurofibroma\" term is already present in the schema, so arbitrarily choosing a subtype without additional information could introduce inaccuracy.\n\nThe critical requirement is matching exact controlled terminology. Lowercase \"neurofibroma\" needs correction to the capitalized \"Neurofibroma\" to align precisely with the schema's specified values.\n\nThe instructions present a nuanced challenge: use exact schema terminology while simultaneously narrowing broad terms. In this specific case, \"Neurofibroma\" serves as the appropriate general term when a more specific classification isn't definitively known.\n\nI'll ensure exact capitalization and terminology match, prioritizing schema compliance while maintaining the core diagnostic intent.",
                "signature": "EvgeCkgIChABGAIqQNGjd9R3xT0Uq+LrlqqfAff7rIszb0tboVMI40527naKN9khjtwmWebDshTMZzFFE4v5E4ALhgFp2HMNY1oQTEQSDOLZHfC1IZujQrGqdxoM1U+LNAotnCcH8Xh9IjBuvBI8yPt+g7kvsSViHjGlerBZqbYuI+dKbwD5kGCZrXrAJKWTwkISDqIffJtTwsMq3R2LHBuPphQDyK1LTyWROEVXQTVMAA3MB1IvA+nttWy+kq3aii5qS3hCqIFZeEU/n1wHPxlmLXozO2m1Ua5qXZWXrFZ2ve96i9P4akxERlmjqWNcBjeWsJj+nhqXuPEGs0Yg18VQrGJhvRvUqkMfkC2l6g7K5ni54zeCwfsQ2REtqY/qcRW8LRQL08QfX7sU67hZh06tt+7eDaRKZAM0A3NxZUncmnf8HGmahNp6blKkJl+vn80bJuRPITebSuvUiWQwBJmkTxnAJj/BTNFP2Tp3rPCyaJdKRvDDOZ5U5JHu0FbQU6c3m2z/RacAkILK3YZ8YqflMJpol9qf/VUl6M15nWMh+vCXjgwEcwvLesP5JDMWqWJC+CN8WNfRT6oX79n9KdptgdP7LamCqe1lokPmBtEcBe2PTMEx5V4ePsBzk0lZOFMKup82SyaLe4cn1yCCSu0QWhchBqYvcsMq+S2voiZXv1mLWTEEF/oWAKOKwVa2kezqRbOBW2dRzGW9gH2MNnKgVqz7fdQ5VwwuN9JfntqVdj47VAfQQeJZIJkQhyX6xoff/prGsq/uIwXHduBYQftKp6QOJRk8WYj999DXS+oGC+ioaQYJdoW71YAU3Qlei3RErSF9IPQEwvYyLUHiMhOJ4fidPVLpM37dPZlET+3ssiUaZpHldxX+eBPPyvqbh8BfLiuJsl9GBvG2SlaOohL8KuhEMKwHJHYe1xPdZV2sI7jpz5vDEkrBrZMQizI9NHG3BcT0+sLmq4OTtDFBAjyqGjP4uqvygkE2lEuxrPqhOHms7cSRtf071B5MsfppL4a1god/GEXJPW9NU6DBACOGp7ani2JHUbUe0ZsmDhsWzFOtDPyV3HTwrkzVbUQWtMyx7EwMYsl06BxRHJyLWS0AcqVUtNRdx4ZcQj8FzhzuQcOrYzCaybpIyfP+o2eiZp6PYMXTfSlcX6da/XqLo3UIqRAStFTENax5VaFKff9Z5ALUX+ZblaLqR9ynKkjiaAYLogdBIlMg6bvkr94fw99rmxA9iRt24dMXBO38mLbSHPIk9EI7AfC9HSqCdh2XuoUqinLJh9n8hiz5ej2Mejx8VXFGkDYucPkQondzztAx4Us7zGHFZWRppEMDbD24XRh/XDk7szanuWF31/8nDuWFeQIr9XOCcMZ3WMUfy+g/3bPjZUmiXENrMToRs+Riw5ZEjwMZW6m3kt5DWf523JvpBoBbf5cgkcQ3zCPBD4KimMW1AJ1CiSYJfQ6pblAIuONg3uHhliO4q1V7WoM4PPRtcU3UmzpFS5DxOykNojUrVZHeUgEU0B6TdrrD1B51R3ZYNCt/j/4X0lRVtnDlaRJkS5P9KJe4Ba0PhJEcd3TNF6fVQ1ZyedKYZiILO1Asn2duXxFT/w87GYMSHfSH8loC2JmLl6pzV6DSxWTQCgu3QNK6+Eh0+mBce7rjNzBxM5CQq0bIAcZvr3OLBNoAVi3Td7ZiznlY/pKdMsaD8svhlclQks4o2n9enLVzI5W5FmsvDdPFy51drNy8n/RYPIeGGYdsCz7z/HX33miIWSUkolPmLr00wvGprneWoz6EefNPW5jMTIbV7Rmzs8Vs9JNxWZnPtCQe129ooJOmfC2kq7k9AGGD/Y5ISkaXwf+5Iy0myWGGPmt0rH+hlwhXriN7dywL1/4YZ6xLVXP/7Mep2fv5qNIofBXkK2Zm5vzcy4waaA7+GpFGVy6TKSWyj0CaYhZiiIns85Cf0yaLJVxvL64g/eTnSbPhTadI4xdlZVcfqXK5/Xut0jrx3SbGulKXaYMh1x1Hl246j9E060Txcy/yPDYRlSV/triNDe9FdWSQvF9YRDSaWUGA5+pSshM8FVHm4B88FZmL1qViYLG/xXcr7vlbNPXO2adfHszjwQc+iD4G0Qu2LZjylw0BDwufz4WiQ0DZZun0aB9/JENlBPTgcDMY45S7i3r6+RuacjRgrPxvg6gKLSRsJf0HiFwKW+xnHy7/6Pu7jK254cGoCnnqG4z8Zzuk9+G81yoovQwcHHJwUhZvLwSuDog6BPUVC7AxZj+6tIwEgqcjgje9qAv+jbAA1LDIIlWk68geYc9Y1v+V3op0kMUsv9ezCW/7y6y9Ki8djHfW5SfZvc6Vc/ZaVP6pOd1CDtiR1JhOyF99lyWJKznYv58lEVmuvD1ZaHIOAOtjmYVPjlli+H7TeyZq2pddMfoHJs6zUlX8H+tZVuCsuzlgV+THOBc3NypnZsVfepdMtNKo3c9jRieOEvvqTMjfygQyXbflCg+QMhMq+0Bxqh/lquIlGgae18bqVZxdcxZpIRtUfkO6Qj+SkiaHHWQ32Sa1QQPBOcvAyXRFacLNzKllKAmfA6kMiYlTLviVTzDaDzLPjCixxdBho907jVZ+/7nIyfIlpO4zCgdbk+yALg1IawO4d2de+nzFdn0K9FZANbZ+YH7mFOUQf/+z+3CWYO4qaiES6e64jiO4qAefPgsFEKzNjCocLI8Rm8HfXP0v8ccUS8wfEqYrRnGmLXtrKM1a0oqjM7VktY5UtGYiLwYXTO2ZU2Yo2u360uhlj9oBIPLARZ0W0B3G/GztfU1QM1hl4Nm4Et/vy8QCloTClv4UzugfYybWRfGkeWprJscd6OupUXHP7Zvfau7rgKd1SaggyT2gDRmi9gnuaJrmz7c4CWS4rI62cZUs62E8euYFP5jq33Z2AfnyvltzRAcC1WCC9ck6c1isuuhWIs+7jQtDC2XrQCeLI23zq8kSw/DWirwyDi5HxCLZi7uGgKdUCtaZ267Ec77ZzHsV0oDBmud1YFZD3UTXXr4PTmhwzK74ysR6MO/7oekndJwU/MC80x6hJb5jn+791vqDbqnSsYsJJIn6Jbx/qidR8vasN10cx6jVgi99r3r2FC5XDmEOK9elV4e0uRtMctgLdK5rAWX6w4UZTZm0PA+f6jGTcayp6SJ6BWyuM1rJiGDS0yaX7hWnNuqBFj1SeRUOBBalieW1maifha9+QrUnVAydy/S5wF22SQ3QSXMohyTRooMP0osHgfp8cGDCpNMSePiifonhJ6ISH7GX5OPtve3uE3bU8tHSC2bTRwmVE/+7raJ1YlctONjPJGQh0QPd0JWrNbquDRvJimvlmPJNkUEOxa0RYd8+fFQRJDQBUdfUhZwq5Rjw9+vLa8XkRjv6iu06rKoyMRVFQ0yckyTgyBoSA8SZhqq9X1ZCpaFKAV1gfBxwqmEnsIzIAjysCJRPGKcYzi1rkuCjQhq9KMF30dWHe5Vti00gxgo7jUor/LL08XVHG5sJMI/1LQgr0qD6eFT4IRV0c+37E3ovXXIgLvVWPel5qL78s2DfAuZtSjOhrHj1heQGg/pa32BK3PnZHkN0BYOUGsVqyqeNh+/F8IwESs9clSoIND5FsYNTNfsttSyWxKNtY+7/OA6dFMcdpJjDr+MH3AhdVbOOFgSejD8FhMw+yBiSto3qjO7MospW46hJhUephjqXJv1lU6dfFvExW424oMbVbQZ7Q5iLaW2/9fxhJh0NQr0Tmj83xUF/KV580X1fhqzh4/YN2SnBJET30gCrHExuzYbPZpLEhJQwII3I2pntyCh7i2BmOXH9F/K0Q5LvrLiht2CG8eLimWIc2WEpkCeiMLtTFsJfI59mOOvmqOZlv/2cgS9t/NaPXnx0UfsPRJuG+d8JtlWIVeCSmHznzzC2Wk+wbIqZ3ZJ5/nbGqE65eamvr4GxMSEZkx8z50LuhC1+wrOCQ0aGFQy7eYrNx5wLjLhafcvnWqQwnTbKTpCRj9Jm3dfXuFmjGyGeXit9HJWkG7NA8vjqsjJ9rRy86kEEFyAreXzKHrydGEao1cBnkrZh1vqzbQmvvwZNjxuFGV7F3pc6zWU3Q48e4ayAR1+P57LktDm+vTHF9FGchQ7stW4wZkgV3s1rN+LhNOssvDZRhyXdS2q1fgqaj6IurFf+zNxE5HUWgiOl+cgiAgDlnWTNywgCfyUB8kiS/pH/fLXELrlhD7bx8GVkLCQVj/5VZmSLBYICN6Ms0qLFD3AnuulWsJv8oCAuEo0D344JOhTotFx/sTxRZV21mwYYR9ulPx/1PxT8KgdANqPPd8Jf/flOkZTArSnEl+IqT8kvgDjgq0KSYjz5xr29/8eqGTXhkE95fduHQ2tn/G7qUZ/kvwkpXhgoR7lJgnrOaDZPKYdvaH88CvfH6arGaUGk3iPdrGjr9IGqMGt20beL19f59xmhcM24dAMn6LoBq0tfLi2G2OIbnTe3MJnkAl9paornCbAShJCi5xwdtk6bIljG7mtXPFniRMmz/UJZrI973YPf1pUyhTJrlQ6ZISQTA163gMBkNjo+Z3sdKLs02/vxaaoxcn2c1cX0rRRN+2dcgOh0GSXlsQ8Jx/9SaLGdL8Y4NOnCkgUCWAy0ejUW9Ja9RjT1q4TUzIrKfBeETylO0emt1/oUf2EwT0L7z7XuTAc/Kag5tKwTr8fDs5D6twtTS98uGbhpVVZlfYcqrSeZlYqzJkqA0xdGOAXaYXnnBlpaWyWEk81SzuVyKS8yB+BXLwShfcd7KdMBI54H/4brAVbK0CLIWnkfxQR4nYX+iNYtdhGMCUbiUUV66BrO7AL8uFsxsVrXR2HVaeflw3QJw3UkdwycW0P1PKHxRkC6HLbWUe+dl9LHFlftBIcCt9Igk+Gxg1AlbzXrUe1rjhFTfUqoVtaqGoyzi7MMbCm6ZIejK1E3izo4UWZ9b86lTX0w//d1ExqLJhOU4wyHZTLuM6y58mYk8uGDi9jZ7M9jw2KjipitBoqIpTyVMoDEzfFsO+1VdpM2wLzxmUcdoA6xIH6sYttiWblVZWRKWlZ0LWnB//UmlNTjVfr9cmuDp8FhQJG1anaDh2SC6m/679MyJRylwXGOWkP+4byJrllk70g/3aRG+XkczDZQEQcVi0NO8CMp9/yq7bdeTSVS1pY8QxI4xcbwUoJeXYyj/4MK0CrcaWCjyJgPmkkTHFtpElAHKw/gXnZfS+uZZoq3tUFA8tMNBwL9q/JdWYRpT4b44BCn4HYHAHR9tagtCfc/4QaWGAE="
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n- **tumorType**: Changed \"neurofibroma\" to \"Neurofibroma\" to match the exact controlled terminology value in the Target Schema (proper capitalization required).\n- **diagnosis** and **assay**: These values already matched the exact controlled terminology and required no changes."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3054,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1179
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Not Applicable",
          "assay": "immunohistochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3054,
          "output_tokens": 1179,
          "total_tokens": 4233
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 5,
        "input": {
          "diagnosis": "neurofibromatosis",
          "assay": "plate based reporter assay",
          "tumorType": "benign neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"massively parallel reporter assay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad term to the specific type 1 variant, which is the most common form of neurofibromatosis.\n\n2. **assay**: \"plate based reporter assay\" \u2192 \"massively parallel reporter assay\" - Narrowed to the specific reporter assay type available in the controlled terminology.\n\n3. **tumorType**: \"benign neurofibroma\" \u2192 \"Neurofibroma\" - Narrowed from the descriptive \"benign\" qualifier to the specific tumor type classification. While more specific subtypes exist in the schema (e.g., Cutaneous Neurofibroma, Plexiform Neurofibroma, Localized Neurofibroma), \"Neurofibroma\" is the appropriate narrowed term without additional context to determine the specific subtype.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3060,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1069
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01Thw6Jq2mh5sJQuK9mEbAtv",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to match the exact controlled terminology from the Target Schema.\n\n1. **diagnosis**: \"neurofibromatosis\"\n   - This is broad and needs to be narrowed\n   - Looking at the enum values, I can see:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n   - The most common form is Neurofibromatosis type 1 (NF1), which is the classic form\n   - Since \"neurofibromatosis\" without specification typically refers to NF1, I should narrow this to \"Neurofibromatosis type 1\"\n\n2. **assay**: \"plate based reporter assay\"\n   - This is a broad term that needs to be matched to the exact enum values\n   - Looking at the available options, the closest match would be:\n     - \"massively parallel reporter assay\" - this is a specific type of reporter assay\n     - However, \"plate based\" suggests a simpler format\n   - Looking more carefully, I don't see an exact \"plate based reporter assay\" in the list\n   - Could be related to:\n     - \"FLIPR high-throughput cellular screening\" - FLIPR is plate-based\n     - \"high content screen\" - also plate-based\n     - \"massively parallel reporter assay\" - a type of reporter assay\n   - Given that it's described as a \"plate based reporter assay\", the most appropriate match would be \"massively parallel reporter assay\" as it's the only reporter assay type in the list\n\n3. **tumorType**: \"benign neurofibroma\"\n   - This needs to be narrowed to a specific type\n   - \"benign neurofibroma\" is broad\n   - Looking at the enum values, there are several specific types of neurofibromas:\n     - \"Neurofibroma\" (general)\n     - \"Cutaneous Neurofibroma\"\n     - Multiple specific subtypes exist\n   - I'll need to carefully match the most precise neurofibroma subtype based on additional clinical details\n\nThe extensive list of neurofibroma subtypes suggests I should seek more specific information to precisely categorize the tumor type. Without additional context, \"Neurofibroma\" remains the most appropriate general classification.\n\nFor the assay field, the massively parallel reporter assay seems the most suitable match, given it's the sole reporter assay type available in the enumeration.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"massively parallel reporter assay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad term to the specific type 1 variant, which is the most common form of neurofibromatosis.\n\n2. **assay**: \"plate based reporter assay\" \u2192 \"massively parallel reporter assay\" - Narrowed to the specific reporter assay type available in the controlled terminology.\n\n3. **tumorType**: \"benign neurofibroma\" \u2192 \"Neurofibroma\" - Narrowed from the descriptive \"benign\" qualifier to the specific tumor type classification. While more specific subtypes exist in the schema (e.g., Cutaneous Neurofibroma, Plexiform Neurofibroma, Localized Neurofibroma), \"Neurofibroma\" is the appropriate narrowed term without additional context to determine the specific subtype."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3060,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1069
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "cell viability assay",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3060,
          "output_tokens": 1069,
          "total_tokens": 4129
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 6,
        "input": {
          "diagnosis": "RASopathy",
          "assay": "immunoassay",
          "tumorType": "NFIB"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"ELISA\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of narrowing:**\n\n1. **diagnosis: \"RASopathy\" \u2192 \"Unknown\"**: \"RASopathy\" is a broad umbrella term referring to genetic syndromes caused by mutations in the RAS/MAPK pathway. While this could include \"Neurofibromatosis type 1\" or \"Noonan Syndrome\" from the controlled vocabulary, without additional context to determine which specific RASopathy is intended, the most accurate narrowing is to \"Unknown\".\n\n2. **assay: \"immunoassay\" \u2192 \"ELISA\"**: \"immunoassay\" is a broad category encompassing various antibody-based detection methods. \"ELISA\" (Enzyme-Linked Immunosorbent Assay) is the most commonly used specific immunoassay technique and represents an appropriate narrowing to a precise, controlled term.\n\n3. **tumorType: \"NFIB\" \u2192 \"Neurofibroma\"**: \"NFIB\" appears to be an abbreviation likely referring to neurofibroma. \"Neurofibroma\" is the appropriate specific controlled term from the schema that corresponds to this abbreviation.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3055,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1674
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01TSM2GQzJBBQ1QvEbjeqZjv",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and match each field to the controlled terminology in the Target Schema.\n\n1. **diagnosis: \"RASopathy\"**\n   - This is a broad term that refers to a group of genetic syndromes caused by mutations in genes in the RAS/MAPK pathway\n   - Looking at the enum values for diagnosis, I can see:\n     - \"Noonan Syndrome\" - this is a RASopathy\n     - \"Neurofibromatosis type 1\" - this is also considered a RASopathy\n   - However, \"RASopathy\" is too broad and could refer to several conditions. In the context of this schema which focuses on NF and related conditions, the most common RASopathies would be NF1 or Noonan Syndrome\n   - Since the original value is just \"RASopathy\" without more specificity, and we need to narrow it, I should probably mark it as \"Unknown\" since we can't determine which specific RASopathy it is\n   - Actually, looking more carefully, Noonan Syndrome is listed as a specific option. But without more context, I cannot definitively say whether \"RASopathy\" should be narrowed to \"Neurofibromatosis type 1\" or \"Noonan Syndrome\" or something else\n   - The safest choice would be \"Unknown\" since we cannot narrow it with certainty\n\n2. **assay: \"immunoassay\"**\n   - This is already in the enum list as \"immunoassay\"\n   - Wait, let me check again... yes, \"immunoassay\" is in the list\n   - Actually, I need to narrow this. \"immunoassay\" is a broad term that could include ELISA, RPPA, proximity extension assay, etc.\n   - Looking at the more specific options:\n     - \"ELISA\"\n     - \"RPPA\" (reverse phase protein array)\n     - \"proximity extension assay\"\n   - Without additional context, I cannot definitively narrow \"immunoassay\" to a specific type. The most common immunoassay in clinical research is ELISA, so this might be the most appropriate choice.\n   - The schema's instructions suggest replacing broad terms with more specific equivalents, which points toward using a precise immunoassay technique.\n   - While \"immunoassay\" is an acceptable enum value, the task emphasizes specificity, making ELISA a reasonable alternative.\n   - However, making this selection requires caution without explicit contextual guidance. I'll narrow \"NFIB\" to \"Neurofibroma\" since it's a general term covering various specific neurofibroma types. Without definitive context, mapping to the broader category seems most appropriate. The abbreviation could represent different specific subtypes, but \"Neurofibroma\" provides the clearest interpretation given the available information.\n\nRegarding diagnosis, while Neurofibromatosis type 1 is a common RASopathy, the lack of precise context means \"Unknown\" remains the most responsible classification. The research setting suggests NF1, but without confirmation, maintaining diagnostic uncertainty is prudent.",
                "signature": "EscoCkgIChABGAIqQOpI5ihvA8aw4RyUzzWVcJrO71VRUkq2sp/f3c2BjTcJs/oKClMQHqJoJ+WpU5nEA1JNGE2NaLKmewVZaPXxWvoSDK5nyx48OBd8Erse/xoMEw/ZTEgtckNQH6FPIjCVf2BDFFoGmZpC/MXkxSZycbP20+gA/PTfOEaWHULGVUXOAGVxIoDd4c81zTCXc2oqrCd+hwBTqSByq2PcY7YvXng8YY82wLvBLBXBXth2nWcA52/HcZNscQYlc6Q9CEjc8U/0f9J5jTEsJYsGuro/YPODb/m/zDXWiXoHNj3VTdzTCmp9+pVuKRABGhg+XBR6BGInv4aTuIpfhDcLJ0kwi7xaRVWn3xIrQc8SsWae9GRCEaOf73bMpvrLwYZPmaVwG6Pl87shN3l1ttwihH5mLSOIabhPqRL+YCwaiGAibaoLtPBxjinGY552Yx4iLhGGaT2bqTw9WFMDxK2xKgs+K+nbkfsKMZPYMsH0qeqge2Mw9kqTBAQX4wYwvC3Z2xPQDk/golLHWsxCsqRF+WdE5mKxdTGS5iclKccyta3T0GuxZNuU7yywD+qJ9t+ik3Tcx3oQMNlbnm3qRac/PwPl1n6ENoawDlR6J+3aAdkbO5H519sFkNYXfa6JaWX1md0LxLl9lg15TxN3jRcsJYpC6Wwy50xrGQZ1n2cyAYrx5cZHw0SW7pjqe3YZGAHGH0wTuZCdqLC9bSLW3pjzbl+yxwxFY4+UI6Aq8z1kp2Bv3RWoFwCAxla04B5vXAfYNFZCsAEB/Ibt2CQYOJcZdpMMGLLrzlIiDXM4S6dFVc1T8p81vnX1pUm3pFw/apObykCUATH6OxBp0gv14xaHz06qvsseq2hw5WKsKFWfzDhBHm7pMaNGKInIH3MKJww48EI5tTjKtLOQq6GPRwLFy3f4gXvkoWiMwU+0pOn8Ym3Gl2t1B87lNGVB5y+JDFK2csVtmvTsSdeAZp8I66a0azsCb94GDVeDwqCUP+9qvnA9bIKQs8VneYNh72vkdbv3oEMaENgTF1v5EAPB4Xzt9wLdJpalX7QnWPnyLSwKvut7aPEGyPRWeGRM4Z9l2PunU0JEd6zw55vbkymeyrVqiTyGdBkQI2Swl7iDPa1lEcNXyewH2N6ewz6Tq1B9Ysb4NJ3SZo/xyFjjMgXH08xiEqep82qobzMiBo/Hxut+8vk9Mn5LD82fG2iptRlnt7BOUA0lBkkYL6Mo9jhpqdJRl1aUy8Oa6S/OIM3YUfMg25N5cGuna17q64UXhddIAljtZQwvHPyEMMCqa7TrDQR/zeRirBCq7wf0C0AFf1O3V4VIisKwU+F1dDcVL7n4U7mNfI6tTuLbazX0rvLFFPdJG5sdG9TRu1Qi/f1ZGVQk6cgMTZOWqZdaQAOrpZIR+V1PQTCaYTvgDNwljEATJq/waAmLZrlhaxJTIrpZdo+YOewR1cB0Zt8uOkOfcYOq0enVe4T3qyeP/jVHJin7//FwMxGeiwtsVT4OBCoRRaKV2/vNdrPZXd0OPMidSCVIU9nFour8/L8mIRyieYYlHcPJ0eFvNvQLg6wd+wkqNizCybLU+wga5HkUl1skdlk5tL4GaQHVRD1ULw5KVw54B6dw9GieqYS4wBMkqWynR7mtgKe7vyFDTHwFWQShDSQNwJMa+7xW/1dfJoxFmi8KQEX2QQHtTMRsvwtBL6sGH/rsHlThlixIXZmGm4hyGEYWGmRcGTqAaYq6IhAbQhHwY1zqXG+HFcw0PuHeClQA1+74ag7MwZY5yrC0thl7+dlgMs/FsVykX2B+G4Fmka4jhcEc3GzSuK7qYlPNaavNIYtB5JcsHMKHCRUYK09MgiSkaCE/xMEcUOqwXOzkJNMyE8v3ODuIhvQz5BLkRv4YopEg54ak6QmOPudCSlEvfFZW2z28FNbmotvAFlA3m3OIocTyJofcrZqvMRqcxWtaK3J9WhnoLilkJioWUD1uSM0Q91RtbbV89ftKhJuUxdn6At+r47vpScpiGWomNqnohfZ6x0Hj8OuYNHuJicqCWMqf0sUcvTMX8DmOdn1R+ShVKyprZhyv4U9Wz1JtAyEa/oOED1HEYvL3JyT43gAtUHDRQE6f3VlaCtgSPJsyhMFb5lMG83B58XO/A+Jyr/ka14kDhM8wQfVnI9N1uk/5z6FyhNRP0LKW4LqQUyXjkz5vwrljAdpEUU0YJpL7PjK4H9IO158GQFL1BYt+hwFHaZr7ixoOmpA5qPcCPcLp1LZNd+C0vBYS3OZGVaPDD+TI/D/kn+PESeRxUYS0Jj85EUQmZ1vDAOplFDvz482o6OWbhrEM1rwpnRDVZI0C+5rWLnLVjEiUniyqdRlbmdVNxnoOFGylOaivUdgUF0PFcXwjFT2SLPj1AnaGiIWQDivd/6aN+Yh0MRA+b5wtezBc3BZGThAcdJDElRT8RPMH8L8IWDAMrp2I8u3f9MjAQJ5QUHPSIGrujmS1UBv+xzFREIQ3b5lZ68lVPwBGBcAkEj+n+WQMVRvSVGAu6Vh3u0gVPuaihgvkZc9PfD5n8OaK/RMb2wU0tmUmEjbE2CGJRWriAE0gTNJx9A70JS10F4H9nnL/lDmMmiTkLsCWsjjlVqDXSb803ALb3iVA4DEOr91u5fO32Lo9MeL4svXiAJ18wbZxxgX4F2KTNgqFIPJdRd9atL9GDyJ2MVuZviwX16Bl+PpD3kFL9SPco5Y/xuWFXaivQQSIsruNMvK/G4YTu3jn9w3jENX80R8kVhKmYSECnnsuFMpxxnyRuKQM9Xlj0Mrslhg2FE4C+nBgI6AFXdiom9kotAwBaUEGiWgSaM0QJ6fLdc9wa+oEEvArQjMFxWVTlIuMXH5xA2DahIFmT8xnXQJpB1jXi4pvAb0BUVr/LDs1S6vJxv8N+GXoq2VY+liqOtvSJhEfTMG31CwyQwNk1taVXvnvxE5hNg5qq1kR2GEk+457Zk+v3cC1CMz2DHdAlMzSxbQkz+r1DsduFj325DNfQIkaXHep7ToD6NB17ZeXM7eWRNiedm+TwbjikK14WgkEGBRk84pADPz+23MrAC/6zzIs1ZNdMvDMNAM1UeAmtTpCJBq9KdBxNtPD/c/kvVzKVaeqbLFsH/ZWvR96gOHzRLV8nYYg3zNarNNm+A3ehDu5VpFy+0cXlTLo7axy4GbT7S0e3wxJITD8NY493aB5P+aa8fGthWP5jdOtVNOP5sltV0ShuwkOWr6/u4imen5EE7eCPjK6VTsRmAIoNyAv4lYKo/XOCAkuvFQJgSjbmNVyWwVXj/fqPtrIWijC9x8ftw/0awGO0KSLx5KGbucJN2usCKWOzQkuEQ0HSB2XFhSh9NohxRj8StPmu6a3S6vY4rEyYSMwJwCtScadNQ6rUWh/e5dGXNr5XC9N1e5YRcY1LqiNxfV9TL+bTBPKhG/A63xQMxzqvVviPWXplJ2iBid0fGeRLnYxhcnGaz4dn4AyGc7DGfb0Qjzu+5Ep4JUWrwIMoQQL/ORLtvCXYUXUYgkDJ2Py2dfpOxxpgcg40ukP9zItXZjOm0GqeHf6MapkrCX8XUQz0yNDOTffRn68otAUnyZXzZ0yDEfGwOmzSzQYAP1LR1ymTXIuKhhJ2GPtRftt8YwUIqIVZUVUmfaEzaLmvoOpJXLqc2WNVvc6n+yivgT7OAF5OaORLijZLLJFEQi1MeZk8u4oS94RFIGxcFf1p8alw12p5CnjBogXYNEAeg2iW/3yYsHn+uA7F/LkdLKZFn1b7AFmwWvaBX4wTuZd6flgL67zR2hBXDfzFFO3lnhcOzbmXnr3elJQ3/SOF0PFL5tMqU9rOLjNWO6QdcTYZ0velE6u8FxH9/ksrT4oxz9cFnh7F28+HYT9U03/7JSMS3d9Nn8YgnyDXdBW0YqhxtfN0nAT7Kzk+YQJplE2DE772AuXJY1VLc3WBIwrhRicEX3K4HmwQXqi/cGSrdwrqVWD45Eu5PHaabHuDPgGr1k+mU7km95hlcYLWrtQ9r7DG/CuyIoGTdt/E/M0QgBsR0ALhNlxl/VuBpMtlwjL1l+2NXnpZHFX3xclRIpZtgSmSeKX0F2ceq2cBDPqfD5iczzXQZ5AJxUp2Jo2U586yFdhQpfqLU6xye+aI/lUBGiPTUUMmnfCL9s9nVTaTvHHsP5w6h+msdRWHJ9ZLmxAjh8/71iDEUszXfQAyaUKuxwo71UYAwhrPrbitug+Z43CDYS7d7VKF6MOZZ0ZgVaQHiSZX+lFavgDUEYCdA63g++IgCm5FpDodzbZJEhXoKiOOD/+YBbmbXUc/GF7wIchhzQi2ag6JvXzg2K9YG03oNGxKuZIYgiHOF3fQBaWrAPZEVVH4+Tjc0MwxlPYQHrJZFuBx+boqy/bp4lMC+wIlufV+dZeakh7HxbjXFT9+1XfX6X9rmYU1Wa+rsuJUBjP9c9ibo9D0BaUGIitMOH6Rn0aGWabwe39Qq5GLJoa7jNBcFiJ/esixW2ZRYbSjkeq5OzQHoEEHG315K6z+KX4dVb5gfmQpy3hArHll/3t2Ts9yy46yJpklBGlY0FYifF3bMPHxFw+RJ3BAhvyRO7hPrOub45JNKiDV8EgzABA4+LrP8EQZlAaQozLvqKT76gc7mq4T8pzLbbwLaLx+RTfVMgrcyAo41WlmkYPiVPEBPyGplklYHIcJ4RkqaStFvrJY5wJeariH7FbEZmCiSQBOHuC51panXDHEdujlydork01EZUwSW7I5IYYyipiPIa3OoXEtwXMs+5RPkKzQOwZHgT4yhCU0OC18/KX8EG5SrHBVi4tIY/eDiivCcExEauMs2B2v+RbhsHUPkyozSzRTGWEPZHhsuFBlkU7AWKbdUUnTJI/eq7+EXrjKtM4E1ev7XV0VRcA/ormtJ9MTfLMlRcjmX2Jn4wxAJT1NQGiIKIWh8s8chBzWWhaiBl2Z90gZGE/lXBo+exSYoMom1s0mkoNb9R3NtQr8eH+KV6zztsIZaaLO5Gj8KyIStUFD6V2w/bx6t4CbmFwNUMo4khKIIw4tnNEjhkDSdL9/iByo3BQn9lQagjp9QTjYNHo3ceaxQDx2JXeucIkeKPsrFO0RGBPFPHhiey7EX2k6jweWi8GcMCJ2bNo5Q4Z7eNRDlDFiiwgsdzdz2wYJH/TrWooPIPoLdutWQup4SOh5ruz0Oy27K7vGfnBZRZARsaIm815FfX760/elVrUpqhG+HEW9VyLSdSkvKL/ASKOOa9PZWl84D6lOCOBDdA10YJNMZcAfgvGRpLHs5dTIP+vRSshf21XMsDeiH7gQCjzEhoW3vQTT25sIvccvgu79YI/GjrfJT37t+5X8OulVltEE2JcNxVxNgWT6E6JCN50XIDw5ypTO8kM8va5HL1Q0rP2XC7t484tdTpJucbCuveLjS4Y7loHdMrDY3/ksvTvbyPPrhneShrwdJEyw9Lujl8FOOAIC46jIxYJY1P5YsdyRG1UCwoG0kKiOWeirshWVhj3yc0AKR2klPBVu9hItA8VUjpI/vtwsQ3jslEz8e/PuT9tHXMHELK4mO7J1LrRoe3/M7CZZyxJSVnlpDB+6cqx+xHft0y6UIeyEVRkwTNDqbEG2J3IYgc09kMQd1ulJxUiS/g06U7CIF9aB8fRLPnDEp9NF2YdIC4bgQDrZvzNEgyWFHefRpGB6FRX4si1V9PshDQphHGnTxZ/QyHNc9Nocfw/SnPE27ALlxTtWcyV8v9s4+pG3zCf+9EDx5yCVEH4qZtCCneObKX8YEWXVTDnxZyDI0h6FcB1iuusDzmeCNxYX96T/5DPYyoOH7/JNNG31GxnmMlzN+ftLIOzzFHe6l1Ag2ot9XXCzyM1/eqdfscKs2UvVBcTz5oViO444/WQW2hL1NEZW9KCuAH/xHrZ3lVFP7B2Rnk86dzXIzNeqkpDAS7J88iTkeN4aILh2Dr9QugnkEQol9O1+pdLRag4LRCqeHTpTJE+uPLRCvKAGwCqVtaV+oRAKUvHBDGIUgdEQrnLqP5UJ4hFJbo8Fa3sfj4gfaSxc7WfxDfyILvzNrAIx6N6rjYsoiRuN1Ihlp8bKP9c5vVdch9l8Zm7I44kkHJl+9WfNjeAAxQjPAqdxHHVOcRzza3GKufnN3alThj+2P/0rX/rQTTDFKo87eTkeNMqaRVYVLevZqYshxfl1dakLvzRnxIMFGggv4zijTmKcxn9G6HXy+kJQ8UglEHTE9VWX/s8acmAWOUmfqu9s8QNLXwP3/hHKjo827HzRzB2wiCXLPs5EHzjEFeaTTGsOvmuHZnggoCLX6uskmmWVRKG/3X7jDebDlfx5Cq1e+Q7ptoPRC6ZymGJwhOhPppHSEmbH2Y70RpFE9zfYqmY02fGVdDY1jDuupklR9+92F4pRUdmFFMX2ouqQ1mNzQxsF9FK4KFSxg9HdE5LIilj7ZrwWbtSHIyROUzLIZ16fcThtQCivtv2ORZWRPGx6uHj27/kpd9ZUQBGMXAL5d8twgjH5lEkGrk07Ldoq32+Da9IXsSWMggVCXIk+dPnJplgcOGcWx6kTjUzkOxUiUVqRVn6QNfvGpM5MPBE3t+7cuBdQXtfgCipHHJZMtzTDvjKbONE4vK/Q1hj8gb8H5dGH9T75j59oj0yDCPsG69iM95WpkVbUWiM5uOxXTOldpG/K8uHhv4Wy4QIOP0Lo4BZWJcOm3jIa84ZOA+rRaeOu2cf+gGJc4BR+7ve41ZFI/bntulZyrkZxREOx+oiUJpQv+zbRA8tmy5HqNZccPiB+ktA3lqKTo62yTdPxaFQCEstrh0qIsw7s+pNqsigv5rVOi1K5Sh0N64XlYZzkLcRH1ibhtDgnExTGL/yAneVH7VX57+VAGqZFB+nsGBQcyTu3WbfNhU6w5Duiqjsge9NDRlCYBgB"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"ELISA\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of narrowing:**\n\n1. **diagnosis: \"RASopathy\" \u2192 \"Unknown\"**: \"RASopathy\" is a broad umbrella term referring to genetic syndromes caused by mutations in the RAS/MAPK pathway. While this could include \"Neurofibromatosis type 1\" or \"Noonan Syndrome\" from the controlled vocabulary, without additional context to determine which specific RASopathy is intended, the most accurate narrowing is to \"Unknown\".\n\n2. **assay: \"immunoassay\" \u2192 \"ELISA\"**: \"immunoassay\" is a broad category encompassing various antibody-based detection methods. \"ELISA\" (Enzyme-Linked Immunosorbent Assay) is the most commonly used specific immunoassay technique and represents an appropriate narrowing to a precise, controlled term.\n\n3. **tumorType: \"NFIB\" \u2192 \"Neurofibroma\"**: \"NFIB\" appears to be an abbreviation likely referring to neurofibroma. \"Neurofibroma\" is the appropriate specific controlled term from the schema that corresponds to this abbreviation."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3055,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1674
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "immunocytochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3055,
          "output_tokens": 1674,
          "total_tokens": 4729
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 7,
        "input": {
          "diagnosis": "NF",
          "assay": "medical imaging",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the abbreviation to the full, specific diagnosis name\n2. **assay**: \"medical imaging\" \u2192 \"conventional MRI\" - Narrowed the broad imaging category to a specific imaging modality commonly used in clinical settings\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\" - Corrected capitalization to match the exact controlled vocabulary value in the schema",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3048,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 718
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01QLG499CTaMhxvJq47PaCuP",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data, I need to narrow the broad synonyms to more specific controlled terminology values from the Target Schema:\n\n1. \"diagnosis\": \"NF\" - This is broad. NF likely stands for Neurofibromatosis. Looking at the enum values, I can see:\n   - \"Neurofibromatosis type 1\"\n   - \"NF2-related schwannomatosis\"\n   \n   Since \"NF\" without qualification is most commonly used to refer to Neurofibromatosis type 1 (NF1), I should narrow this to \"Neurofibromatosis type 1\".\n\n2. \"assay\": \"medical imaging\" - This is a very broad term. Looking at the enum values for assay, there are several specific imaging techniques:\n   - \"conventional MRI\"\n   - \"diffusion MRI\"\n   - \"functional MRI\"\n   - \"structural MRI\"\n   - \"resting state functional MRI\"\n   - \"Magnetization-Prepared Rapid Gradient Echo MRI\"\n   - \"magnetic resonance angiography\"\n   - \"magnetic resonance spectroscopy\"\n   - \"ultrasound\"\n   - \"high frequency ultrasound\"\n   - \"x-ray\"\n   - \"x-ray computed tomography\"\n   - \"positron emission tomography\"\n   - \"optical coherence tomography\"\n   - \"optical tomography\"\n   - \"3D imaging\"\n   \n   The most general medical imaging term that's still specific would be \"conventional MRI\" as MRI is one of the most common medical imaging modalities used in neurofibromatosis research. However, \"3D imaging\" or \"x-ray\" could also be candidates. I think \"conventional MRI\" is a good choice as it's commonly used in NF research and is more specific than just \"medical imaging\" but still general enough to cover common medical imaging scenarios.\n\n3. \"tumorType\": \"unknown\" - Looking at the enum values, I can see \"Unknown\" with a capital U. \n\nThe schema requires \"Unknown\" with proper capitalization. All three values are present in their respective enums, so I can proceed with the mapping.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the abbreviation to the full, specific diagnosis name\n2. **assay**: \"medical imaging\" \u2192 \"conventional MRI\" - Narrowed the broad imaging category to a specific imaging modality commonly used in clinical settings\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\" - Corrected capitalization to match the exact controlled vocabulary value in the schema"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3048,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 718
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 3048,
          "output_tokens": 718,
          "total_tokens": 3766
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 8,
        "input": {
          "diagnosis": "neurocristopathy",
          "assay": "transcriptomics",
          "tumorType": "neurolemmoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Schwannomatosis-NOS\",\n  \"assay\": \"transcriptomics\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"neurocristopathy\" (a broad term for neural crest-derived disorders) to **\"Schwannomatosis-NOS\"** (Not Otherwise Specified), which is a more specific condition affecting neural crest-derived Schwann cells and aligns with the schwannoma tumor type indicated.\n\n2. **assay**: \"transcriptomics\" is already an exact match in the Target Schema controlled vocabulary, so no change was needed.\n\n3. **tumorType**: Narrowed \"neurolemmoma\" (an older synonym) to **\"Schwannoma\"**, which is the current standard terminology for this benign nerve sheath tumor.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3056,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1031
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01Phvu7pMrRT1EoCSYz5BBwt",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific terms from the Target Schema.\n\n1. **diagnosis: \"neurocristopathy\"**\n   - Neurocristopathy refers to disorders affecting neural crest-derived tissues\n   - Looking at the enum values in the schema, conditions related to neural crest include:\n     - Neurofibromatosis type 1 (affects neural crest-derived tissues)\n     - Schwannomatosis (various types)\n     - Vestibular Schwannoma\n   - Since \"neurocristopathy\" is very broad and could refer to any of these conditions, and without more context, I should look for a more general but still valid term from the schema\n   - However, all the options are quite specific. The most appropriate narrowing might be to one of the schwannomatosis or NF conditions, but \"Unknown\" might also be appropriate if we can't determine which specific neurocristopathy it is\n   - Actually, looking more carefully, Neurofibromatosis type 1 is a common neurocristopathy, and schwannomatosis is also a neurocristopathy. Since the context shows this is related to schwannoma (neurolemmoma in tumorType), Schwannomatosis might be most appropriate\n   - Let me reconsider: \"Schwannomatosis-NOS\" (Not Otherwise Specified) might be the best narrowing for a general neurocristopathy when we have limited information\n\n2. **assay: \"transcriptomics\"**\n   - This is already in the enum list! \"transcriptomics\" is an exact match in the Target Schema\n   - So this one stays as is\n\n3. **tumorType: \"neurolemmoma\"**\n   - Neurolemmoma is another name for schwannoma\n   - Looking at the enum, \"Schwannoma\" is available\n   - This should be narrowed to \"Schwannoma\"\n\nWait, let me reconsider the diagnosis. \n\nI'm focusing on the schwannoma connection and neural crest disorder. The tumor's characteristics point towards a specific type of schwannomatosis. Sporadic schwannoma emerges as a potential precise classification, considering the broad neurocristopathy context and the specific tumor type. The key is matching the general neural crest disorder with the most appropriate, specific diagnostic term available in the schema.\n\nThe diagnostic approach requires balancing generality with specificity, selecting a term that captures the essential clinical features without over-narrowing the potential diagnostic range.\n\n\"Schwannomatosis-NOS\" provides a nuanced classification that acknowledges the schwannoma's complexity while maintaining diagnostic flexibility.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Schwannomatosis-NOS\",\n  \"assay\": \"transcriptomics\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"neurocristopathy\" (a broad term for neural crest-derived disorders) to **\"Schwannomatosis-NOS\"** (Not Otherwise Specified), which is a more specific condition affecting neural crest-derived Schwann cells and aligns with the schwannoma tumor type indicated.\n\n2. **assay**: \"transcriptomics\" is already an exact match in the Target Schema controlled vocabulary, so no change was needed.\n\n3. **tumorType**: Narrowed \"neurolemmoma\" (an older synonym) to **\"Schwannoma\"**, which is the current standard terminology for this benign nerve sheath tumor."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3056,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1031
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "NF2-related schwannomatosis",
          "assay": "RNA-seq",
          "tumorType": "schwannoma"
        },
        "token_usage": {
          "input_tokens": 3056,
          "output_tokens": 1031,
          "total_tokens": 4087
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 9,
        "input": {
          "diagnosis": "phakomatosis",
          "assay": "viability assay",
          "tumorType": "tumor of cranial and spinal nerves"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Schwannomatosis\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Rationale for narrowing:**\n\n1. **diagnosis**: \"phakomatosis\" \u2192 \"Schwannomatosis\"\n   - Phakomatosis is a broad term for neurocutaneous syndromes. Given the context of tumors of cranial and spinal nerves, Schwannomatosis is the most appropriate specific diagnosis, as it is characterized by multiple schwannomas affecting cranial and spinal nerves.\n\n2. **assay**: \"viability assay\" \u2192 \"cell viability assay\"\n   - \"Viability assay\" is a general term. \"Cell viability assay\" is the specific controlled term in the schema that represents standard in vitro viability testing methods.\n\n3. **tumorType**: \"tumor of cranial and spinal nerves\" \u2192 \"Schwannoma\"\n   - Tumors of cranial and spinal nerves are most specifically represented by schwannomas, which are benign nerve sheath tumors arising from Schwann cells that occur on cranial and spinal nerves.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3060,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1276
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01SqjFbLpXAuopCCh3cAtkGE",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific controlled terminology from the Target Schema:\n\n1. **diagnosis**: \"phakomatosis\"\n   - Phakomatoses are neurocutaneous syndromes. Looking at the enum values, the relevant diagnoses include:\n   - Neurofibromatosis type 1 (NF1)\n   - NF2-related schwannomatosis\n   - Schwannomatosis variants\n   - Since \"phakomatosis\" is very broad and can refer to several conditions including NF1, NF2, etc., but the most common and general one that would fit would be \"Neurofibromatosis type 1\" as it's one of the most common phakomatoses. However, without more context, this is difficult. Let me think...\n   - Actually, looking at the options, \"Unknown\" might be appropriate if we can't determine which specific phakomatosis it is. But if we're narrowing, we should pick a specific one.\n   - Given that NF1 is the most common phakomatosis in this list, I'll narrow it to \"Neurofibromatosis type 1\"\n\n2. **assay**: \"viability assay\"\n   - Looking at the enum values for assay, there are several specific viability assays:\n   - \"2D AlamarBlue absorbance\"\n   - \"2D AlamarBlue fluorescence\"\n   - \"3D microtissue viability\"\n   - \"cell viability assay\"\n   - \"in vivo PDX viability\"\n   - The most direct narrowing of \"viability assay\" would be \"cell viability assay\" as it's the most general specific term for viability assays in the list.\n\n3. **tumorType**: \"tumor of cranial and spinal nerves\"\n   - Tumors of cranial and spinal nerves in the context of phakomatoses would typically be:\n   - Schwannoma (especially for NF2)\n   - Neurofibroma (for NF1)\n   - Malignant Peripheral Nerve Sheath Tumor\n   - Given the broad term \"tumor of cranial and spinal nerves,\" the most appropriate narrow term would be \"Schwannoma\" as these are the classic tumors of cranial nerves (like vestibular schwannoma/acoustic neuroma) and spinal nerves. However, if the diagnosis is NF1, then \"Neurofibroma\" would be more appropriate.\n   - Since I narrowed diagnosis to NF1, I should consider \"Neurofibroma\" OR \"Schwannoma.\" Since neurofibromas are more characteristic of NF1, I'll select \"Neurofibroma\" for consistency with the diagnosis.\n\nWait, I need to reconsider. The term \"phakomatosis\" is extremely broad and could refer to multiple conditions. Looking at the diagnosis options\u2014NF1, NF2-related schwannomatosis, various schwannomatosis types, and Noonan Syndrome\u2014these are all phakomatoses. The tumor location on cranial and spinal nerves points toward NF2, which classically presents with bilateral vestibular schwannomas.\n\nBut schwannomatosis itself is characterized by multiple schwannomas. Since the tumor type specifically involves cranial and spinal nerves where schwannomas develop, I'm leaning toward a schwannomatosis-related diagnosis. Let me settle on \"Schwannomatosis\" as the diagnosis, \"cell viability assay\" for the assay, and \"Schwannoma\" as the tumor type.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Schwannomatosis\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Rationale for narrowing:**\n\n1. **diagnosis**: \"phakomatosis\" \u2192 \"Schwannomatosis\"\n   - Phakomatosis is a broad term for neurocutaneous syndromes. Given the context of tumors of cranial and spinal nerves, Schwannomatosis is the most appropriate specific diagnosis, as it is characterized by multiple schwannomas affecting cranial and spinal nerves.\n\n2. **assay**: \"viability assay\" \u2192 \"cell viability assay\"\n   - \"Viability assay\" is a general term. \"Cell viability assay\" is the specific controlled term in the schema that represents standard in vitro viability testing methods.\n\n3. **tumorType**: \"tumor of cranial and spinal nerves\" \u2192 \"Schwannoma\"\n   - Tumors of cranial and spinal nerves are most specifically represented by schwannomas, which are benign nerve sheath tumors arising from Schwann cells that occur on cranial and spinal nerves."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3060,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1276
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "3D microtissue viability",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3060,
          "output_tokens": 1276,
          "total_tokens": 4336
        },
        "tool_calls": [],
        "tool_execution_history": []
      }
    ],
    "metrics": {
      "total_samples": 10,
      "successful_runs": 10,
      "failed_runs": 0,
      "success_rate": 1.0,
      "average_score": 0.4,
      "min_score": 0.0,
      "max_score": 1.0,
      "num_scored": 10
    },
    "duration_seconds": 191.12824249267578,
    "token_usage": {
      "input_tokens": 30562,
      "output_tokens": 10943,
      "total_tokens": 41505
    }
  }
}